Altamira Therapeutics announced its transition from NASDAQ to OTCQB marketplace following a delisting notice from the Nasdaq Hearings Panel on December 18, 2024. The delisting, effective December 20, 2024, results from the company’s failure to maintain the required minimum bid price of $1.00 per share under Nasdaq’s Rule 5550(a)(2).
The company will continue trading under the ticker symbol CYTOF on the OTCQB platform, ensuring uninterrupted market activity for shareholders with no action required. Altamira had previously received a delisting notification on September 30, 2024, and appealed to present its compliance plan, which was ultimately denied by the Panel.
Altamira Therapeutics ha annunciato la sua transizione dal NASDAQ al mercato OTCQB a seguito di un avviso di delisting ricevuto dal Nasdaq Hearings Panel il 18 dicembre 2024. Il delisting, efficace dal 20…
